- Home
- FENC vs GALT Comparison
FENC vs GALT Comparison
Compare FENC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | GALT |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 199.2M |
| IPO Year | 2010 | 2008 |
Fundamental Metrics
Financial Performance| Metric | FENC | GALT |
|---|---|---|
| Price | $8.91 | $2.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $14.50 | $8.50 |
| AVG Volume (30 Days) | ★ 385.5K | 302.5K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $870.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $1.33 |
| 52 Week High | $10.45 | $7.13 |
Technical Indicators
Market Signals| Indicator | FENC | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 58.21 |
| Support Level | $7.40 | $2.62 |
| Resistance Level | $9.15 | $3.24 |
| Average True Range (ATR) | 0.52 | 0.21 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 20.41 | 43.86 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.